Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
To access the live webcast of the fireside chat, please contact your B. Riley Securities sales representative.
Following the event, an archived replay of the fireside chat will be available on the investors section of the Company’s website at www.verastem.com.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111104814/en/
Investors:
Ryan Porter
Argot Partners
+1 212-600-1902
ryan.porter@argotpartners.com
Media:
Lisa Buffington
Corporate Communications
+1 781-292-4502
lbuffington@verastem.com
Source: Verastem Oncology